ERBB2 and neoplasm: F/B significantly increases in the tumor bulk with NACT administration (5.25 ± 0.36 (biopsy) versus 6.24 ± 0.37 (excision); paired t-test, p = 0.015, Figure 3a), but not in the tumor-stroma interface of HER2+ samples (7.26 ± 0.49 (biopsy) versus 7.62 ± 0.43 (excision); paired t-test, p = 0.54, Figure 3b).